Getting older usually comes with a frustrating little ritual: holding menus farther away, squinting at texts, and surrendering to reading glasses whether you like it or not. But that entire routine may be heading for extinction. The FDA has officially approved a once-daily prescription eye drop called VIZZ, and the buzz around it is exploding for one reason — it could help millions read clearly again without reaching for glasses.
The science behind it sounds almost too simple. One drop in each eye per day. That’s it. Within about 30 minutes, users can reportedly see nearby text more sharply, and the effect can last up to 10 hours. No surgery. No lasers. No bulky lenses hanging from your shirt collar.
The active ingredient, aceclidine, actually isn’t new. It’s been around since the 1970s and was originally used to treat glaucoma. But researchers discovered something unexpected: the drug gently shrinks the pupil, creating what’s known as a “pinhole effect.” It’s basically the same trick your eyes use when you squint to bring blurry text back into focus.
What makes VIZZ stand out is what it doesn’t do. Earlier vision drops, like Vuity, worked by forcing the eye’s focusing muscles to contract, which caused complaints ranging from headaches to blurry distance vision and strange visual distortion. VIZZ reportedly avoids those problems entirely because it works differently.
The treatment was tested across more than 30,000 treatment days without major complications, and the estimated cost is around $2 a day. That’s a potentially massive shift for the millions entering their 40s and suddenly struggling to read fine print. With presbyopia expected to affect nearly 2 billion people worldwide by 2030, this isn’t just another eye drop. It could be the beginning of the end for reading glasses altogether.
click and follow Indiaherald WhatsApp channel